Tuesday, June 25, 2024
SOPHiA GENETICS, a leader in healthcare technology specializing in data-driven medicine, has unveiled its new Residual Acute Myeloid (RAM) Application. This latest addition expands the company's oncology portfolio to include support for measurable residual disease (MRD) capabilities, set to be available globally starting this summer.
Acute Myeloid Leukemia (AML), though rare, is one of the most common forms of leukemia in adults, with a significant number of patients experiencing relapse within three years of achieving complete remission. Post-treatment monitoring is crucial during the first two years to quickly detect any signs of relapse.
MRD solutions are vital for guiding post-remission therapy, detecting early relapse, and serving as a primary endpoint in clinical trials to improve patient outcomes.
Chief Medical Officer and Chief Product Officer at SOPHiA GENETICS, highlighted the importance of MRD measurement and monitoring in optimizing therapy sequencing for AML.
The SOPHiA DDM™ RAM Solution aims to transform clinical research by enabling longitudinal tracking of individual mutation evolution through its dedicated module on the SOPHiA DDM™ Platform.
Using next-generation sequencing (NGS) technology, the SOPHiA DDM™ RAM Solution ensures highly sensitive MRD testing, capable of detecting one cancer cell among 10,000 cells.
It provides analytical capabilities down to 0.01% Variant Allele Frequency (VAF) and covers essential genes recommended in guidelines, offering robust insights into acute myeloid disease response.
Customers will benefit from the solution's longitudinal variant monitoring, which allows visualization of each patient's mutational landscape over time. It integrates up-to-date databases and customizable reporting features to generate graphical representations and comprehensive MRD reports.
Moreover, the SOPHiA DDM™ RAM Solution continuously enhances its machine learning algorithms to deliver accurate MRD results within four days, demonstrating its commitment to advancing precision medicine in oncology.
Source: prnewswire.com
